Do analysts recommend UPC or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 376.19%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, UPC or ERNA?

Universe Pharmaceuticals has higher revenue and earnings than Ernexa Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A Ernexa Therapeutics $580K 12.71 -$14.08M -$26.20 N/A

Is UPC or ERNA more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Ernexa Therapeutics N/A -263.74% -151.16%

Which has stronger earnings & valuation, CNSP or UPC?

Universe Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A

Is CNSP or UPC more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Universe Pharmaceuticals N/A N/A N/A

Do analysts recommend UPC or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, UPC or TNFA?

Universe Pharmaceuticals has higher revenue and earnings than TNF Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A

Is UPC or TNFA more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A TNF Pharmaceuticals N/A -69.21% -33.98%

Does the media refer more to UPC or TNFA?

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 1 mentions for TNF Pharmaceuticals. TNF Pharmaceuticals' average media sentiment score of 0.95 beat Universe Pharmaceuticals' score of 0.00 indicating that TNF Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Universe Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TNF Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend UPC or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, UPC or GNPX?

Universe Pharmaceuticals has higher revenue and earnings than Genprex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A Genprex N/A N/A -$16.23M -$14.14 N/A

Is UPC or GNPX more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Genprex N/A -247.32% -176.73%

Does the media prefer UPC or GNPX?

In the previous week, Genprex had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 4 mentions for Genprex and 2 mentions for Universe Pharmaceuticals. Genprex's average media sentiment score of 0.63 beat Universe Pharmaceuticals' score of 0.00 indicating that Genprex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Universe Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genprex 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ACXP or UPC?

Universe Pharmaceuticals has higher revenue and earnings than Acurx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A

Is ACXP or UPC more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Universe Pharmaceuticals N/A N/A N/A

Universe Pharmaceuticals (UPC) Competitors

$2.95 -0.09 (-2.96%)

Closing price 04:00 PM Eastern

Extended Trading

$2.81 -0.14 (-4.71%)

As of 07:56 PM Eastern

Compare

UPC vs. ERNA, CNSP, TNFA, GNPX, and ACXP

Should you buy Universe Pharmaceuticals stock or one of its competitors? MarketBeat compares Universe Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Universe Pharmaceuticals include Ernexa Therapeutics (ERNA), CNS Pharmaceuticals (CNSP), TNF Pharmaceuticals (TNFA), Genprex (GNPX), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry.

How does Universe Pharmaceuticals compare to Ernexa Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 376.19%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Universe Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.49, indicating that its stock price is 149% more volatile than the broader market.

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 0 mentions for Ernexa Therapeutics. Universe Pharmaceuticals' average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
Ernexa Therapeutics	Neutral

Universe Pharmaceuticals' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Universe Pharmaceuticals has higher revenue and earnings than Ernexa Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A
Ernexa Therapeutics	$580K	12.71	-$14.08M	-$26.20	N/A

Summary

Universe Pharmaceuticals and Ernexa Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Universe Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A

CNS Pharmaceuticals presently has a consensus target price of $20.00, suggesting a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Universe Pharmaceuticals	N/A	N/A	N/A

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Universe Pharmaceuticals	Neutral

Summary

Universe Pharmaceuticals beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to TNF Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Universe Pharmaceuticals has higher revenue and earnings than TNF Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 1 mentions for TNF Pharmaceuticals. TNF Pharmaceuticals' average media sentiment score of 0.95 beat Universe Pharmaceuticals' score of 0.00 indicating that TNF Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Universe Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TNF Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Universe Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Universe Pharmaceuticals beats TNF Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Genprex?

Universe Pharmaceuticals (NASDAQ:UPC) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Universe Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Genprex	N/A	-247.32%	-176.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Genprex has a beta of -0.98, suggesting that its stock price is 198% less volatile than the broader market.

In the previous week, Genprex had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 4 mentions for Genprex and 2 mentions for Universe Pharmaceuticals. Genprex's average media sentiment score of 0.63 beat Universe Pharmaceuticals' score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Universe Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genprex	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Universe Pharmaceuticals has higher revenue and earnings than Genprex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Summary

Universe Pharmaceuticals beats Genprex on 6 of the 9 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Universe Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Universe Pharmaceuticals	N/A	N/A	N/A

Universe Pharmaceuticals has higher revenue and earnings than Acurx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A

Acurx Pharmaceuticals presently has a consensus target price of $31.00, indicating a potential upside of 2,008.84%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Acurx Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 0 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
Universe Pharmaceuticals	Neutral

Summary

Universe Pharmaceuticals beats Acurx Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPC vs. The Competition

Export

Metric	Universe Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71M	$2.99B	$6.54B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	N/A	18.65	25.39	23.96
Price / Sales	0.09	341.96	530.17	107.90
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	0.03	4.14	10.76	6.41
Net Income	-$3.67M	$64.45M	$3.56B	$337.14M
7 Day Performance	1.37%	1.34%	1.37%	-0.48%
1 Month Performance	9.46%	0.95%	0.81%	0.49%
1 Year Performance	-18.28%	24.33%	30.53%	28.16%

Universe Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPC Universe Pharmaceuticals	0.7955 of 5 stars	$2.95 -3.0%	N/A	-19.4%	$1.71M	$17.86M	N/A	220
ERNA Ernexa Therapeutics	3.0621 of 5 stars	$6.30 +2.4%	$30.00 +376.2%	-89.7%	$7.17M	$580K	N/A	10
CNSP CNS Pharmaceuticals	2.39 of 5 stars	$4.74 -3.1%	$20.00 +321.9%	-52.9%	$7.15M	N/A	N/A	5	Gap Down
TNFA TNF Pharmaceuticals	0.2451 of 5 stars	$3.87 +1.3%	N/A	-71.1%	$7.15M	N/A	N/A	6	News Coverage
GNPX Genprex	1.1988 of 5 stars	$0.49 -24.0%	N/A	-95.4%	$7M	N/A	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Universe Pharmaceuticals (UPC) Competitors

UPC vs. ERNA, CNSP, TNFA, GNPX, and ACXP

How does Universe Pharmaceuticals compare to Ernexa Therapeutics?

Summary

How does Universe Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does Universe Pharmaceuticals compare to TNF Pharmaceuticals?

Summary

How does Universe Pharmaceuticals compare to Genprex?

Summary

How does Universe Pharmaceuticals compare to Acurx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Universe Pharmaceuticals (UPC) Competitors

UPC vs. ERNA, CNSP, TNFA, GNPX, and ACXP

How does Universe Pharmaceuticals compare to Ernexa Therapeutics?

Do analysts recommend UPC or ERNA?

Which has more risk & volatility, UPC or ERNA?

Do institutionals and insiders believe in UPC or ERNA?

Does the media prefer UPC or ERNA?

Is UPC or ERNA more profitable?

Which has preferable valuation & earnings, UPC or ERNA?

Summary

How does Universe Pharmaceuticals compare to CNS Pharmaceuticals?

Which has stronger earnings & valuation, CNSP or UPC?

Do analysts rate CNSP or UPC?

Is CNSP or UPC more profitable?

Do institutionals & insiders have more ownership in CNSP or UPC?

Which has more volatility and risk, CNSP or UPC?

Does the media favor CNSP or UPC?

Summary

How does Universe Pharmaceuticals compare to TNF Pharmaceuticals?

Which has stronger valuation & earnings, UPC or TNFA?

Does the media refer more to UPC or TNFA?

Which has more volatility & risk, UPC or TNFA?

Do insiders and institutionals have more ownership in UPC or TNFA?

Is UPC or TNFA more profitable?

Do analysts recommend UPC or TNFA?

Summary

How does Universe Pharmaceuticals compare to Genprex?

Is UPC or GNPX more profitable?

Do analysts recommend UPC or GNPX?

Which has more risk & volatility, UPC or GNPX?

Does the media prefer UPC or GNPX?

Do institutionals and insiders have more ownership in UPC or GNPX?

Which has preferable valuation and earnings, UPC or GNPX?

Summary

How does Universe Pharmaceuticals compare to Acurx Pharmaceuticals?

Which has more risk and volatility, ACXP or UPC?

Do insiders and institutionals believe in ACXP or UPC?

Is ACXP or UPC more profitable?

Which has preferable valuation and earnings, ACXP or UPC?

Do analysts rate ACXP or UPC?

Does the media favor ACXP or UPC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools